Cargando…
Risk Factors for Central Lymph Node Metastases and Benefit of Prophylactic Central Lymph Node Dissection in Middle Eastern Patients With cN0 Papillary Thyroid Carcinoma
BACKGROUND: Prophylactic central lymph node dissection (PCLND) for adult patients with papillary thyroid carcinoma (PTC) is still a matter of debate. Data on incidence, risk and benefits of PCLND in Middle Eastern patients is lacking. Therefore, we aimed to identify the incidence and predictive clin...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8801573/ https://www.ncbi.nlm.nih.gov/pubmed/35111686 http://dx.doi.org/10.3389/fonc.2021.819824 |
_version_ | 1784642490358300672 |
---|---|
author | Parvathareddy, Sandeep Kumar Siraj, Abdul K. Ahmed, Saeeda O. DeVera, Felisa Al-Sobhi, Saif S. Al-Dayel, Fouad Al-Kuraya, Khawla S. |
author_facet | Parvathareddy, Sandeep Kumar Siraj, Abdul K. Ahmed, Saeeda O. DeVera, Felisa Al-Sobhi, Saif S. Al-Dayel, Fouad Al-Kuraya, Khawla S. |
author_sort | Parvathareddy, Sandeep Kumar |
collection | PubMed |
description | BACKGROUND: Prophylactic central lymph node dissection (PCLND) for adult patients with papillary thyroid carcinoma (PTC) is still a matter of debate. Data on incidence, risk and benefits of PCLND in Middle Eastern patients is lacking. Therefore, we aimed to identify the incidence and predictive clinico-pathological and molecular marker of PCLND in adult patients with clinically node negative (cN0) Middle Eastern PTC. METHODS: This retrospective study included 942 adult Middle Eastern patients with cN0 PTC who underwent total thyroidectomy (TT) or TT+PCLND. Clinico-pathological associations of central lymph node metastasis (CLNM) were assessed. Multivariate analysis was performed using logistic regression and Cox proportional hazards model. RESULTS: 213 patients underwent PCLND and 38.0% (81/213) had positive CLNM. Multivariate analysis demonstrated age ≤55 years (Odds Ratio (OR) = 7.38; 95% Confidence Interval (CI) = 1.59 – 34.31; p = 0.0108), tumor bilaterality (OR = 3.01; 95% CI = 1.01 – 9.21; p = 0.0483), lymphovascular invasion (OR = 2.92; 95% CI = 1.18 – 7.23; p = 0.0206) and BRAF mutation (OR = 3.24; 95% CI = 1.41 – 7.49; p = 0.0058) were independent predictors of CLNM in adult PTC. Furthermore, patients who underwent PCLND showed significant association with improved recurrence-free survival (RFS; p = 0.0379). Multivariate analysis demonstrated that PCLND was an independent predictor of improved recurrence-free survival. CONCLUSIONS: cN0 Middle Eastern PTC patients treated with PCLND showed a significantly better prognosis. PCLND was effective in improving RFS in Middle Eastern PTC patients and should be encouraged for patients with potential risk factors for CLNM. |
format | Online Article Text |
id | pubmed-8801573 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-88015732022-02-01 Risk Factors for Central Lymph Node Metastases and Benefit of Prophylactic Central Lymph Node Dissection in Middle Eastern Patients With cN0 Papillary Thyroid Carcinoma Parvathareddy, Sandeep Kumar Siraj, Abdul K. Ahmed, Saeeda O. DeVera, Felisa Al-Sobhi, Saif S. Al-Dayel, Fouad Al-Kuraya, Khawla S. Front Oncol Oncology BACKGROUND: Prophylactic central lymph node dissection (PCLND) for adult patients with papillary thyroid carcinoma (PTC) is still a matter of debate. Data on incidence, risk and benefits of PCLND in Middle Eastern patients is lacking. Therefore, we aimed to identify the incidence and predictive clinico-pathological and molecular marker of PCLND in adult patients with clinically node negative (cN0) Middle Eastern PTC. METHODS: This retrospective study included 942 adult Middle Eastern patients with cN0 PTC who underwent total thyroidectomy (TT) or TT+PCLND. Clinico-pathological associations of central lymph node metastasis (CLNM) were assessed. Multivariate analysis was performed using logistic regression and Cox proportional hazards model. RESULTS: 213 patients underwent PCLND and 38.0% (81/213) had positive CLNM. Multivariate analysis demonstrated age ≤55 years (Odds Ratio (OR) = 7.38; 95% Confidence Interval (CI) = 1.59 – 34.31; p = 0.0108), tumor bilaterality (OR = 3.01; 95% CI = 1.01 – 9.21; p = 0.0483), lymphovascular invasion (OR = 2.92; 95% CI = 1.18 – 7.23; p = 0.0206) and BRAF mutation (OR = 3.24; 95% CI = 1.41 – 7.49; p = 0.0058) were independent predictors of CLNM in adult PTC. Furthermore, patients who underwent PCLND showed significant association with improved recurrence-free survival (RFS; p = 0.0379). Multivariate analysis demonstrated that PCLND was an independent predictor of improved recurrence-free survival. CONCLUSIONS: cN0 Middle Eastern PTC patients treated with PCLND showed a significantly better prognosis. PCLND was effective in improving RFS in Middle Eastern PTC patients and should be encouraged for patients with potential risk factors for CLNM. Frontiers Media S.A. 2022-01-17 /pmc/articles/PMC8801573/ /pubmed/35111686 http://dx.doi.org/10.3389/fonc.2021.819824 Text en Copyright © 2022 Parvathareddy, Siraj, Ahmed, DeVera, Al-Sobhi, Al-Dayel and Al-Kuraya https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Parvathareddy, Sandeep Kumar Siraj, Abdul K. Ahmed, Saeeda O. DeVera, Felisa Al-Sobhi, Saif S. Al-Dayel, Fouad Al-Kuraya, Khawla S. Risk Factors for Central Lymph Node Metastases and Benefit of Prophylactic Central Lymph Node Dissection in Middle Eastern Patients With cN0 Papillary Thyroid Carcinoma |
title | Risk Factors for Central Lymph Node Metastases and Benefit of Prophylactic Central Lymph Node Dissection in Middle Eastern Patients With cN0 Papillary Thyroid Carcinoma |
title_full | Risk Factors for Central Lymph Node Metastases and Benefit of Prophylactic Central Lymph Node Dissection in Middle Eastern Patients With cN0 Papillary Thyroid Carcinoma |
title_fullStr | Risk Factors for Central Lymph Node Metastases and Benefit of Prophylactic Central Lymph Node Dissection in Middle Eastern Patients With cN0 Papillary Thyroid Carcinoma |
title_full_unstemmed | Risk Factors for Central Lymph Node Metastases and Benefit of Prophylactic Central Lymph Node Dissection in Middle Eastern Patients With cN0 Papillary Thyroid Carcinoma |
title_short | Risk Factors for Central Lymph Node Metastases and Benefit of Prophylactic Central Lymph Node Dissection in Middle Eastern Patients With cN0 Papillary Thyroid Carcinoma |
title_sort | risk factors for central lymph node metastases and benefit of prophylactic central lymph node dissection in middle eastern patients with cn0 papillary thyroid carcinoma |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8801573/ https://www.ncbi.nlm.nih.gov/pubmed/35111686 http://dx.doi.org/10.3389/fonc.2021.819824 |
work_keys_str_mv | AT parvathareddysandeepkumar riskfactorsforcentrallymphnodemetastasesandbenefitofprophylacticcentrallymphnodedissectioninmiddleeasternpatientswithcn0papillarythyroidcarcinoma AT sirajabdulk riskfactorsforcentrallymphnodemetastasesandbenefitofprophylacticcentrallymphnodedissectioninmiddleeasternpatientswithcn0papillarythyroidcarcinoma AT ahmedsaeedao riskfactorsforcentrallymphnodemetastasesandbenefitofprophylacticcentrallymphnodedissectioninmiddleeasternpatientswithcn0papillarythyroidcarcinoma AT deverafelisa riskfactorsforcentrallymphnodemetastasesandbenefitofprophylacticcentrallymphnodedissectioninmiddleeasternpatientswithcn0papillarythyroidcarcinoma AT alsobhisaifs riskfactorsforcentrallymphnodemetastasesandbenefitofprophylacticcentrallymphnodedissectioninmiddleeasternpatientswithcn0papillarythyroidcarcinoma AT aldayelfouad riskfactorsforcentrallymphnodemetastasesandbenefitofprophylacticcentrallymphnodedissectioninmiddleeasternpatientswithcn0papillarythyroidcarcinoma AT alkurayakhawlas riskfactorsforcentrallymphnodemetastasesandbenefitofprophylacticcentrallymphnodedissectioninmiddleeasternpatientswithcn0papillarythyroidcarcinoma |